drugset / Trial / NCT03396250

A Pharmacokinetic Trial of Naproxen Sodium and Diphenhydramine Hydrochloride Soft Capsules Versus Naproxen Sodium and Diphenhydramine Hydrochloride Tablets in Healthy Adult Subjects

NCT03396250

Phase 1 Completed 36 enrolled Bayer
RandomizedCrossoverOpen-labelTreatment

Summary

To evaluate the relative bioavailability of Naproxen Sodium 220 mg and diphenhydramine hydrochloride (DPH HCL) 25 mg soft capsules (Test) versus Naproxen Sodium 220 mg and diphenhydramine hydrochloride 25 mg tablets (Reference) after a single oral administration under fasted condition in healthy adults subjects. To assess the safety and tolerability of the investigational products in terms of advent events (AEs) and clinical parameters.

Timeline

Start
2018-02-12
Primary completion
2018-03-26
Completion
2018-03-29

Drugs

EvaluationDrugModalityDoseRoute
Subject Diphenhydramine Unknown 25 mg Oral
Subject Naproxen Small molecule 220 mg Oral

Indications

No indication recorded.